Skip to search formSkip to main contentSkip to account menu

AN 238

Known as: AN-238 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

DoxorubicinPyrroles
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin
As there is no effective systemic therapy for advanced hepatocellular carcinoma (HCC), we investigated the presence of receptors… 
2005
2005
Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1
Chemoresistance mediated by membrane transporters such as multidrug resistance (MDR‐1) glycoprotein remains a challenge in the… 
2005
2005
Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238
The cytotoxic analogue of somatostatin, AN‐238, consisting of 2‐pyrrolinodoxorubicin (AN‐201), a superactive derivative of… 
2004
2004
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
PURPOSE The targeted cytotoxic somatostatin analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to carrier… 
2003
2003
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas
New modalities are necessary for the treatment of patients with unresectable gastric carcinoma. The authors investigated whether… 
Highly Cited
2002
Highly Cited
2002
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
The resistance of advanced colorectal cancers to therapy is often related to mutations in the p53 tumor suppressor gene. Because… 
Highly Cited
2001
Highly Cited
2001
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
Highly Cited
2000
Highly Cited
2000
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
The effectiveness of chemotherapy targeted to somatostatin (SST) receptors based on cytotoxic SST analogue AN-238, consisting of… 
2000
2000
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Receptors for somatostatin (SST) found on brain tumors could be used for targeting of chemotherapeutic agents. This study was… 
1999
1999
Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238
Since somatostatin (sst) receptors are expressed in a high percentage of human breast cancers, we studied the effects of a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)